Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
Figure 2
Effect of lenalidomide on the apoptosis of leukemia cells. (a) PBMCs from CLL patients () were cultured in the presence of 1 μM lenalidomide or DMSO for 7 days and apoptosis was analyzed by staining with annexin V. The figure shows the flow cytometric profile of annexin V staining of leukemia cells from a representative patient after lenalidomide treatment (numbers in the dot plot represent the percentage of cells). (b) PBMCs (ranging from 70% to 95% of leukemia cells) from CLL patients () were cultured as detailed in and apoptosis of leukemia cells was studied by annexin V staining. The scatterplot represents the percentage of apoptosis in DMSO versus lenalidomide-treated cells. (c) The bars represent the mean and the standard deviation of the fold induction of annexin V-positive leukemia cells (, Mann-Whitney U test). (d) Correlation between annexin V staining of leukemia cells and the percentage of nonleukemia immune cells of CLL patients. (e) Correlation between annexin V labeling of leukemia cells and the percentage of NKT-like cells (CD3+CD8+CD56+) of CLL patients.
